Physician profile
Eric Alter
NPI 1225370901
$1,068.83
in general payments reported to CMS, 2019-2025
11 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.54 · 2020: $24.50 · 2021: $34.98 · 2022: $74.19 · 2023: $109 · 2024: $120 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $512.50 | 2019-2025 | |
| Heartflow, INC. | $147.59 | 2025 | |
| Merck Sharp & Dohme LLC | $109.04 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.93 | 2020-2025 | Lifevest |
| Pfizer INC. | $55.82 | 2023-2025 | |
| Abbott Laboratories | $33.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.70 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $31.31 | 2025 | Camzyos |
| Amgen INC. | $25.22 | 2025 | Repatha |
| Janssen Biotech, INC. | $22.81 | 2023 | Remicade, Stelara, Simponi Aria |
| Medtronic, INC. | $18.82 | 2023 | Corevalve Evolut R |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Alter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.